GlobeNewswire Inc | Jan 5, 2022 07:00AM EST

January 05, 2022

TORONTO and HOUSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (Medicenna or the Company) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that company managementwill be participating in the following virtual investor conferences taking place in January 2022.

Details are as follows:

11th Annual LifeSci Partners Corporate Access Event (January 5 7, 2022)Format: Panel Presentation and 1x1 investor meetings Panel Title: Next Gen Immune-Oncology: Moving Beyond PD-1 and CTLA-4 Panel Date: January 7, 2022Panel Time: 7:30 a.m. ET Webcast Link: https://wsw.com/webcast/lifesci3/panel12/2460150To request a meeting, register for the event here.

H.C. Wainwright BIOCONNECT Virtual Conference (January 10 13, 2022)Format: On demand Presentation Date: Beginning Monday, January 10, 2022Time: 7:00 a.m. ET

Biotech Showcase2022 (January 10 12 and 17 19, 2022)Format: 1x1 investor meetingsTo request a meeting, register for the event here.

About Medicenna Medicenna is a clinical stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Superkines. Medicenna's long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity thereby preferentially stimulating cancer killing effector T cells and NK cells. Medicennas early-stage BiSKITs program, (BifunctionalSuperKineImmunoTherapies)is designed to enhance the ability of Superkines to treat immunologically cold tumors. Medicenna's IL-4 Empowered Superkine, MDNA55, has been studied in 5 clinical trials including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. MDNA55 has obtained Fast-Track and Orphan Drug status from the FDA and FDA/EMA, respectively.

Forward-Looking StatementThis news release contains forward-looking statements under applicable securities laws and relate to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects", "believes", "seeks" and similar expressions. All statements other than statements of historical fact, included in this release, including the future plans and objectives of the Company, are forward-looking statements that are subject to risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the risks detailed in the annual information form and Form 40-F of the Company and in other filings made by the Company with the applicable securities regulators from time to time inCanadaandtheUnited States.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. Except as required by law, we do not intend and do not assume any obligation to update or revise publicly any of the included forward-looking statements.

Further Information

For further information about the Company please contact:

Elizabeth Williams, Chief Financial Officer, 416-648-5555, ewilliams@medicenna.com

Investor Contact

For more investor information, please contact:

Dan Ferry, Managing Director, LifeSci Advisors, 617-430-7576, daniel@lifesciadvisors.com